News
6h
Zacks Investment Research on MSNNovo Nordisk (NVO) Beats Stock Market Upswing: What Investors Need to KnowIn the latest close session, Novo Nordisk (NVO) was up +1.89% at $71.01. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. Meanwhile, the Dow gained 0.43%, and the Nasdaq, ...
Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...
14h
Zacks Investment Research on MSNLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
The state law gives Gov. Lamont "an enormous amount of negotiating leverage with the industry," Sen. Lesser said.
Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...
The number of reported measles cases in the United States has hit 1,288 in the first six months of this year, the most since ...
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Novo Nordisk A/S (NYSE: NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results